Inflation and the Covid-19 pandemic have put pharmaceutical productivity front and center in recent years. Thus, drug companies are under mounting pressure to prove that new treatments are safe and ...
In this free webinar, gain insight into how model-informed drug development uses early PK/PD data, extrapolation and simulation to enable earlier, regulator-ready pediatric dose selection with fewer ...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances ...
The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development process for industry and patients. Our two companies are applying AI in ...
RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief ...
In this episode, we are joined by Patrick Smith, PharmD, President, Integrated Drug Development, Certara and Lynne Yao, MD, Director, Division of Pediatric and Maternal Health, US FDA. They give us an ...
RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President ...
Hosted on MSN
Certara appoints Jon Resnick as new CEO
Certara ( (CERT)) has provided an update. On December 11, 2025, Certara, a leader in model-informed drug development, announced the appointment of Jon Resnick as the new Chief Executive Officer, ...
Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and development RADNOR, Pa., July 31, 2025 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results